Vol. 21 No. 1 (2017)
REVIEWS

A clinical importance of natriuretic peptides in pediatric practice

PDF (Русский)
  • E. Saperova,
  • I. Vakhlova
E. Saperova
Ural State Medical University, Ministry of Health Care of Russian Federation, 620028 Ekaterinburg, Russian Federation
Bio
I. Vakhlova
Ural State Medical University, Ministry of Health Care of Russian Federation, 620028 Ekaterinburg, Russian Federation
DOI: https://doi.org/10.21688/1681-3472-2017-1-117-127

Published 2017-04-26

Keywords

  • natriuretic peptide,
  • heart failure,
  • congenital heart disease,
  • pediatric practice

How to Cite

Saperova, E., & Vakhlova, I. (2017). A clinical importance of natriuretic peptides in pediatric practice. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 21(1), 117–127. https://doi.org/10.21688/1681-3472-2017-1-117-127

Copyright (c) 2017 Saperova E.V., Vakhlova I.V.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Natriuretic peptides (NUP) are peptide hormones secreted by cardiomyocytes in response to a volume overload of the heart. Emphasis in the article is placed on the history of NUP discovery, their chemical structure and pathophysiological mechanisms of action. The data on determination of NUP reference values in children with cardiac pathologies are analyzed. A NUP clinical significance in early diagnosis of heart failure in children, including those with congenital heart defects is shown. Also considered is NUP dynamics after surgical correction of congenital heart defects. A conclusion is drawn that NUP play an important prognostic role in evaluating early and late postoperative periods and disease outcomes on a whole.

Received 11 October 2016. Accepted 22 December 2016.

Funding: The study had no sponsorship.

Conflict of interest: The authors declare no conflict of interest.

Author contributions

All authors contributed equally at all stages of the research.

PDF (Русский)

References

  1. Andreev DA. Natrijureticheskie peptidy V-tipa pri serdechnoj nedostatochnosti: diagnostika, ocenka prognoza i jeffektivnosti lechenija. Laboratornaya meditsina. 2003;6. Available at: https://ramld.ru/articles/article.php?id=22. (accessed: 3.10.2016) (In Russ.)
  2. Basargina EN, Leonteva IV, Kotlukova NP, Kovalev IA, Sharykin AS. Diagnostika i lechenie hronicheskoj serdechnoj nedostatochnosti u detej i podrostkov: metodicheskie rekomendacii Moscow, Assotsiatsiya detskikh kardiologov Rossii, 2010. 80 p. (In Russ.)
  3. Emets GV, Kuzmenko SA, Zhovnir VA. Heart failure in children. Sovremennaya pediatriya = Current pediatrics. 2013;6:172-6. (In Russ.)
  4. Zhelev VA, Baranovskaya SV, Mikhalev YeV, Filippov GP, Serebrov VYu, Yermolenko SP, Popova YuYu. Clinical-biochemical markers of myocardial lesions in premature neonates. Bulletin of Siberian Medicine. 2007;6(4):86-90. (In Russ.)
  5. Eliseev OM. Natriuretic peptides. Evolution of knowledge. Terapevticheskij arkhiv = Therapeutic archive. 2003;75(9):40-6. (In Russ.)
  6. Nagornaya NV, Pshenichnaya EV, Bordyugova YeV. Clinical value of brain natriuretic peptide indicator in patients with heart failure. Zdorove rebenka. 2011;2:115-20. (In Russ.)
  7. Bugrimova MA. Klinicheskoe znachenie otsenki urovnya mozgovogo natriyureticheskogo peptida i sistolicheskoy funktsii miokarda u bolnykh s khronicheskoy serdechnoy nedostatochnostyu. Kand, Diss. Moscow, 2007. 28 p. (In Russ.)
  8. Bozkurt B, Mann DL. Use of biomarkers in management of heart failure. Circulation. 2003;107(9):1231-3. https://doi.org/10.1161/01.CIR.0000057608.97285.20
  9. Lisy M, Babal P. Brain natriuretic peptide – the biological marker in the diagnosis of overt congestive heart failure and myocardial ischemia. Bratisl Lek Listy. 2007;108(4-5):170-3.
  10. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens. 1992;10(10):1111-4.]
  11. Markery serdechno-sosudistoj nedostatochnosti. Available at: http://www.biochemmack.ru/upload/uf/411/411436f66d7a694a862947cab2868f8b.pdf (accessed 28.06.2016) (In Russ.)
  12. Baynes JW, Dominiczak MH. Water and Electrolyte Homeostasis. Medical biochemistry. Elsevier Store; 2014. pp. 320-32.
  13. De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362(9380):316-22. https://doi.org/10.1016/S0140-6736(03)13976-1
  14. Oishi PE, Field-Ridley A, Datar SA, Fineman JR. B-type natriuretic peptide in neonates, infants and children undergoing cardiac surgery. Front Lines of Thoracic Surgery. InTech; 2012. pp. 199-212.
  15. Wu YR, Chen SB, Huang MR, Zhang YQ, Sun K, Chen S. Diagnostic value of the currently used criteria and brain natriuretic peptide for diagnosing congestive heart failure in children with congenital heart disease. Zhonghua Er Ke Za Zhi. 2006;44(10):728-32.
  16. Fedotova IN, Belopolsky AA, Sturov NV. Diagnostic value of NT-proBNP in cardiac patients. Trudny patient = Difficult patient. 2013;7:22-32. (In Russ.)
  17. Woods RL. Cardioprotective function of atrial natriuretic peptide and B-type natriuretic peptide: a brief review. Clin Exp Pharmacol Physiol. 2004;31(11):791-4. https://doi.org/10.1111/j.0305-1870.2004.04073.x
  18. Andrjuhin AN. Osobennosti vedeniya bolnykh s serdechnoy nedostatochnostyu i sokhranennoy sistolicheskoy funktsiey v obshchey praktike. Kand, Diss. St.Petersburg, 2013. 22 p. (In Russ.)
  19. Weber M, Hamm C. Role of B–type natriuretic peptide (BNP) and NT–proBNP in clinical routine. Heart. 2006;92(6):843-9. https://doi.org/10.1136/hrt.2005.071233
  20. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors and cyclic guanosine monophosfate-dependent signaling functions. Endocr Rev. 2006;27(1):47-72. https://doi.org/10.1210/er.2005-0014
  21. Maisel AS, Clopton P, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc Ph, Omland T, Storrow AB, Abraham WT, Wu AHB, Steg G, Westheim A, Knudsen CW, Perez A, Kazanegra R, Bhalla V, Herrmann HC, Aumont MC, McCullough PA. Impact of age, race, and sex on the ability of b-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the breathing not properly (bnp) multinational study. Am. Heart J. 2004;147(6):1-12. https://doi.org/10.1016/j.ahj.2004.01.013
  22. Federalnye klinicheskie rekomendatsii po okazaniyu meditsinskoy pomoshchi detyam s khronicheskoy serdechnoy nedostatochnostyu. Available at: http://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/_kr_hsn.pdf. (accessed: 10.08.2016) (In Russ.)
  23. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, Clopton P, Alberto J, Hlavin P, Maisel AS. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in a urgent-care setting. J Am Coll Cardiol. 2001;37(2):379-85.
  24. Maher KO, Reed H, Cuadrado A, Simsic J, Mahle WT, DeGuzman M, Leong T, Bandyopadhyay S. B-Type Natriuretic peptide in the emergency diagnosis of critical heart disease in children. Pediatrics. 2008;121(6):1484-8. https://doi.org/10.1542/peds.2007-1856
  25. Das BB. Plasma B-type natriuretic peptides in children with cardiovascular diseases. Pediatric cardiology. 2010;31(8):1135-45. https://doi.org/10.1007/s00246-010-9758-x
  26. Law YM, Hoyer AW, Reller MD, Silberbach M. Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children. Study. Journal of the American College of Cardiology. 2009;54(15):1467-75. https://doi.org/10.1016/j.jacc.2009.06.020
  27. Cantinotti M, Storti S, Ripoli A, Zyw L, Crocetti M, Assanta N, Murzi B, Clerico A. Diagnostic accuracy of B-type natriuretic hormone for congenital heart disease in the first month of life. Clinical chemistry and laboratory medicine. 2010;48(9):1333-8. https://doi.org/10.1515/CCLM.2010.251
  28. Mareev VJu, Ageev FT, Arutjunov GP, Koroteev AV, Mareev JuV, Ovchinnikov AG, Belenkov JuN, Vasjuk JuA, Galjavich AS, Garganeeva AA, Giljarevskij SR, Glezer MG, Koziolova NA, Koc JaI, Lopatin JuM, Martynov AI, Moiseev VS, Revishvili ASh, Sitnikova MJu, Skibickij VV, Sokolov EI, Storozhakov GI, Fomin IV, Chesnikova AI, Shljahto EV. SEHF, RSC AND RSMSIM national guidelines on CHF diagnostics and treatment (fourth revision). approved at the sehf congress on December 7, 2012, at the SEHF board of directors meeting on march 31, 2013, and at the RSC congress on September 25, 2013. Serdechnaja nedostatochnost = Russian Heart Failure Journal]. 2013;14(7):379-472. (In Russ.)
  29. Bionda C, Bergerot C, Ardail D, Rodriguez-Lafrasse C, Rousson R. Plasma BNP and NT-proBNP assays by automated immunoanalyzers: analytical and clinical study. Ann Clin Lab Sci. 2006;36(3):299-306.
  30. McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Sandberg Rev Cardiovasc Med. 2003;4(4):S13-9.
  31. Koch A, Rauh M, Zink S, Singer H. Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age. Acta Paediatr. 2006;95(7):805-9. https://doi.org/10.1080/08035250500466647
  32. Hammerer-Lercher A, Geiger R, Mair J, Url C, Tulzer G, Lechner E, Puschendorf B, Sommer R. Utility of N-Terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients. Clin Chem. 2006;52(7):1415-9. https://doi.org/10.1373/clinchem.2005.060608
  33. Cohen S, Springer C, Avital A, Perles Z, Rein AJ, Argaman Z, Nir A. Amino-terminal proB-type natriuretic peptide: heart or lung disease in pediatric respiratory distress? Pediatrics. 2005;115(5):1347-50. https://doi.org/10.1542/peds.2004-1429
  34. Koch A, Singer H. Normal values of B-type natriuretic peptide in infants, children, and adolescents. Heart. 2003;89(8):875-8.
  35. Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, Koch A, Falkenberg J, Mir TS. NT-Pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol. 2009;30(1):3-8. https://doi.org/10.1007/s00246-008-9258-4
  36. Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJ. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence: Elevated levels at birth and in heart diseases. Acta Paediatr. 2004;93(5):603-7.
  37. Yoshibayashi M, Kamiya T, Saito Y, Nakao K, Nishioka K, Temma S, Itoh H, Shirakami G, Matsuo H. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol. 1995;133(2):207-9.
  38. Mir TS, Flato M, Falkenberg J, Haddad M, Budden R, Weil J, Albers S, Laer S. Plasma concentrations of N-terminal pro-B-type natriuretic peptide in healthy children, adolescents and young adults: effect of age and general. Pediatr Cardiol. 2006;27(1):73-7. DOI: https://doi.org/10.1007/s00246-005-1022-4
  39. Schwachtgen L, Herrmann M, Georg T, Schwarz P, Marx N, Lindinger A. Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children. Z. Kardiol. 2005;94(6):399-404. https://doi.org/10.1007/s00392-005-0246-x
  40. Mir TS, Laux R, Hellwege HH, Liedke B, Heinze C, von Buelow H, Läer S, Weil J. Plasma concentration of amino aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics. 2003;112(4):896-9.
  41. Koch A, Zink S, Singer H, Dittrich S. B-type natriuretic peptide in pediatric patients with congenital heart disease. Eur Heart J. 2006;27(7):861-6. https://doi.org/10.1016/j.ejheart.2007.11.001
  42. Man BL, Cheung YF. Plasma brain natriuretic peptide and systemic ventricular function in asymptomatic patients late after the Fontan procedure. Heart and vessels. 2007;22(6):398-403. https://doi.org/10.1007/s00380-007-0993-x
  43. Cowley CG, Bradley JD, Shaddy RE. B-type natriuretic peptide levels in congenital heart disease. Pediatr Cardiol. 2004;25(4):336-40. https://doi.org/10.1007/s00246-003-0461-z
  44. Law Y.M, Keller BB, Feingold BM, Boyle GJ. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patient with congenital heart disease. Amer J Cardiol. 2005;95(4):474-78. https://doi.org/10.1016/j.amjcard.2004.10.014
  45. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int. 2003;45(3):249-54.
  46. Kunii Y, Kamada M, Ohtsuki S, Araki T, Kataoka K, Kageyama M, Nakagawa N, Seino Y. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama. 2003;57(4):191-7.
  47. Mainwaring RD, Parise C, Wright SB, Juris AL, Achtel RA, Fallah H. Brain natriuretic peptide levels before and after ventricular septal defect repair. The Annals of thoracic surgery. 2007;84(6):2066-9. https://doi.org/10.1016/j.athoracsur.2007.07.021
  48. Sanjeev S, Pettersen M, Lua J, Thomas R, Shankaran S, L'Ecuyer T. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinato. 2005;25(11):709-13. https://doi.org/10.1038/sj.jp.7211383
  49. Choi BM, Lee KH, Eun BL, Yoo KH, Hong YS, Son CS, Lee JW. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatric. 2005;115(3):255-61. https://doi.org/10.1542/peds.2004-1837
  50. Amirnovin R, Keller RL, Herrera Ch, Hsu JH, Datar S, Karl TR, Adatia I, Oishi P, Fineman J. R. B-type natriuretic peptide levels predict outcomes in infants undergoing cardiac surgery in a lesion-dependent fashion. J Thorac Cardiovasc Surg. 2013;145(5):1279-87. https://doi.org/10.1016/j.jtcvs.2012.07.067
  51. Niedner MF, Foley JL, Riffenburgh RH, Bichell DP, Peterson BM, Rodarte A. B-type natriuretic peptide: perioperative patterns in congenital heart disease. Congenital heart disease. 2010;5(3):243-55. https://doi.org/10.1111/j.1747-0803.2010.00396.x
  52. Hsu JH, Oishi PE, Keller RL, Chikovani O, Karl TR, Azakie A, Adatia I, Fineman JR. Perioperative B-type natriuretic peptide levels predict outcome after bidirectional cavopulmonary anastomosis and total cavopulmonary connection. J Thorac Cardiovasc Surg. 2008;135(4):746-53. https://doi.org/10.1016/j.jtcvs.2007.10.040
  53. Paul MA, Backer CL, Binns HJ, Mavroudis C, Webb CL, Yogev R, Franklin WH. B-type natriuretic peptide and heart failure in patients with ventricular septal defect: a pilot study. Pediatric cardiology. 2009;30(8):1094-7. https://doi.org/10.1007/s00246-009-9503-5
  54. Koch AM, Zink S, Glöckler M, Seeliger T, Dittrich S. Plasma levels of B-type natriuretic peptide in patients with tetralogy of Fallot after surgical repair. Int J Cardiol. 2010;143(2):130-4. https://doi.org/10.1016/j.ijcard.2009.01.062
  55. Pietrzak R, Werner B. Usefulness of NT-proBNP in assessment of right ventricular function in children after tetralogy of Fallot correction - a preliminary stud. Kardiol Pol. 2009;67(4):378-83.
  56. Dodge-Khatami A, Buchel EV, Knirsch W, Kadner A, Rousson V, Dave HH, Bauersfeld U, Pretre R. Brain natriuretic peptide and magnetic resonance imaging in tetralogy with right ventricular. The Annals of thoracic surgery. 2006;82(3):983-8. https://doi.org/10.1016/j.athoracsur.2006.03.038
  57. Koch A, Kitzsteiner T, Zink S, Cesnjevar R, Singer H. Impact of cardiac surgery on plasma levels of B-type natriuretic peptide in children with congenital heart disease. Int J Cardiol. 2007;114(1):339-44. https://doi.org/10.1016/j.ijcard.2006.01.022
  58. Shih СY, Sapru A, Oishi P, Azakie A, Karl TR, Harmon C, Asija R, Adatia I, Fineman JR. Alterations in plasma B-type natriuretic peptide levels after repair of congenital heart defects: a potential perioperative marker. Surgery for Congenital Heart Disease. 2006;131(3):632-8. https://doi.org/10.1016/j.jtcvs.2005.10.052
  59. Sun L. S., Dominguez C., Mallavaram N.A., Quaegebeur J.M. Dysfunction of atrial and B-type natriuretic peptides in congenital univentricular defects. J. Thorac. Cardiovasc. Surg. 2005;129(5):1104-1110. DOI: https://doi.org/10.1016/j.jtcvs.2004.08.025
  60. Law YM, Ettedgui J, Beerman L, Maisel A, Tofovic S. Comparison of plasma B-type natriuretic peptide levels in single ventricle patients with systemic ventricle heart failure versus isolated cavopulmonary failure. Am J Cardiol. 2006;98(4):520-4. https://doi.org/10.1016/j.amjcard.2006.02.058
  61. Berry JG, Askovich B, Shaddy RE, Hawkins JA, Cowley CG. Prognostic value of B-type natriuretic peptide in surgical palliation of children with single-ventricle congenital heart disease. Pediatr Cardiol. 2007;29(1):70-5. https://doi.org/10.1007/s00246-007-9012-3
  62. Atz AM, Zak V, Breitbart RE, Colan SD, Pasquali SK, Hsu DT, Lu M, Mahony L, Paridon SM, Puchalski MD, Geva T, McCrindle BW. Factors аassociated with serum Brain natriuretic peptide levels after the Fontan procedure. Congenital heart disease. 2011;6(4):313-21. https://doi.org/10.1111/j.1747-0803.2011.00496.x
  63. Koch AM, Zink S, Singer H. B-type natriuretic peptide in patients with systemic right ventricle. Cardiology. 2008;110(1):1-7. https://doi.org/10.1159/000109399
  64. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Europ Heart J. 2003;24(19):1735-43.
  65. De Sutter J, De Bacquer D, Cuypers S, Delanghe J, De Buyzere M, Kornitzer M, De Backer G. Plasma N-terminal pro-brain natriuretic peptide concentration predicts coronary events in men at work: a report from the BELSTRESS study. European Heart Journal. 2005;26(24):2644-9. https://doi.org/10.1093/eurheartj/ehi502
  66. Talwar S, Squire I, Downie P, Davies J, Ng L, Baxter G. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. European Heart Journal. 1999;20(4):1736-44. https://doi.org/10.1136/heart.84.4.421
  67. Hsu JH, Keller RL, Chikovani O, Cheng H, Hollander SA, Karl TR, Azakie A, Adatia I, Oishi P, Fineman JR. B-type natriuretic peptide levels predict outcome after neonatal cardiac surgery. J Thorac Cardiovasc Surg. 2007;134(4):939-45. https://doi.org/10.1016/j.jtcvs.2007.04.017
  68. Claudius I, Lan YT, Chang RK, Wetzel GT, Alejos J. Usefulness of B-type natriuretic peptide as a noninvasive screening tool for cardiac allograft pathology in pediatric heart transplant recipients. Am J Cardiol. 2003;92(11):1368-70. https://doi.org/10.1016/j.amjcard.2003.08.035
  69. Knirsch W, Häusermann E, Fasnacht M, Hersberger M, Gessler P, Bauersfeld U. Plasma B-type natriuretic peptide levels in children with heart disease. Acta Paediatr. 2011;100(9):1213-6. https://doi.org/10.1111/j.1651-2227.2011.02258.x
  70. Holmgren D, Westerlind A, Berggren H, Lundberg PA, Wahlander H. Increased natriuretic peptide type B level after the second palliative step in children with univentricular hearts with right ventricular morphology but not left ventricular morphology. Pediatric cardiology. 2008;29(4):786-92. https://doi.org/10.1007/s00246-008-9201-8